1.	Phase III Randomized Study of Incorporating IFF into Neoadjuvant and Adjuvant DOX/CDDP/MTX Chemotherapy and of MTP-PE During and After Maintenance Chemotherapy in Newly Diagnosed, Resectable Osteogenic Sarcoma Phase: Phase III Type: Treatment Status: Closed Age: not over 30 Sponsor: NCI Protocol IDs: CCG-7921, POG-9351, INT-0133
2.	Phase II Study of Liposomal Muramyl Tripeptide Phosphatidylethanolamine in Patients with Advanced Soft Tissue Sarcomas (Summary Last Modified 11/91) Phase: Phase II Type: Treatment Status: Closed Age: 15 to 75 Sponsor: Protocol IDs: EORTC-62911
3.	Phase II Pilot Study of CGP 19835A Lipid with Either IFF or CDDP in Patients with Osteosarcoma Who Have Failed Prior Adjuvant Therapy (Summary Last Modified 08/92) Phase: Phase II Type: Treatment Status: Closed Age: 8 to 70 Sponsor: Protocol IDs: MSKCC-91103, NCI-V91-0188
4.	Phase I Immunotherapy with the Muramyl Tripeptide Derivative CGP19835A Encapsulated in Liposomes in Patients with Cancer (Summary Last Modified 06/97) Phase: Phase I Type: Treatment Status: Completed Age: 18 to 70 Sponsor: NCI Protocol IDs: BRMP-8605A, NCI-86-C-161A, NCI-T86-0249N, T86-0249
5.	Phase I Immunotherapy with Liposome-Encapsulated CGP 19835A in Patients with AIDS-Related Kaposi's Sarcoma (Summary Last Modified 01/88) Phase: Phase I Type: Treatment Status: Completed Age: 18 to 70 Sponsor: NIAID Protocol IDs: NIAID-86-I-181, NCI-V86-0147
6.	L-MTP-PE for High-Risk Osteosarcoma Phase: No phase specified Type: Treatment Status: Closed Age: 2 to 50 Sponsor: Pharmaceutical / Industry Protocol IDs: MTP-OS-403, NCT00631631